Protective effect of peroxisome proliferator activator receptor (PPAR)-α and -γ Ligands against methotrexate-induced nephrotoxicity

Immunopharmacology and Immunotoxicology

Volumn 36, Issue 2, 2014, Pages 130-137

  Ibrahim, Mohamed A ^a   El Sheikh, Azza A K ^a   Khalaf, Hanaa M ^a   Abdelrahman, Aly M ^a  

^a Minia University   (Egypt)

Author keywords

Fnofibrate; Nitric oxide; Oxidative stress; Pioglitazone; TNF

Indexed keywords

CASPASE 3; CATALASE; CREATININE; FENOFIBRATE; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MALONALDEHYDE; METHOTREXATE; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HISTOPATHOLOGY; KIDNEY FUNCTION; MALE; NEPHROTOXICITY; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; UPREGULATION; UREA BLOOD LEVEL;

ANIMALS; APOPTOSIS; CASPASE 3; CREATININE; KIDNEY; LIGANDS; MALE; MALONDIALDEHYDE; METHOTREXATE; NF-KAPPA B; NITRIC OXIDE; OXIDATIVE STRESS; PPAR ALPHA; PPAR GAMMA; RATS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84897876031     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923973.2014.884135     Document Type: Article

References (31)

1. Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol 2009;146: 489-503.
2. Messmann R, Allegra C. Antifolates. In: Chabner B, Longo D, eds. Cancer chemotherapy and biotherapy. Philadelphia: Lippincott Williams & Wilkins; 2001: 139-184.
3. Vardi N, Parlakpinar H, Ates B, et al. The protective effects of Prunus armeniaca L (apricot) against methotrexate-induced oxidative damage and apoptosis in rat kidney. J Physiol Biochem 2013;69: 371-381.
4. Caǧlar Y, Ozgür H, Matur I, et al. Ultrastructural evaluation of the effect of N-acetylcysteine on methotrexate nephrotoxicity in rats. Histol Histopathol 2013;28: 865-874.
5. Guan Y, Breyer MD. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int 2001;60: 14-30.
6. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990;347: 645-650.
7. Dreyer C, Krey G, Keller H, et al. Control of the peroxisomal betaoxidation pathway by a novel family of nuclear hormone receptors. Cell 1992;68: 879-887.
8. Zhou Y, Kong X, Zhao P, et al. Peroxisome proliferator-activated receptor-α is renoprotective in doxorubicin-induced glomerular injury. Kidney Int 2011;79: 1302-1311.
9. Jun M, Zhu B, Tonelli M, et al. Effects of fibrates in kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol 2012;60: 2061-2071.
10. Cheng CF, Chen HH, Lin H. Role of PPARα and its agonist in renal diseases. PPAR Res 2010;2010:345098. doi: 10.1155/2010/345098.
11. Iglesias P, Díez JJ. Peroxisome proliferator-activated receptors agonists in renal disease. Euro J Endocrinol 2006;154: 613-621.
12. Gelosa P, Banfi C, Gianella A, et al. Peroxisome proliferatoractivated receptor. Agonism prevents renal damage and the oxidative stress and inflammatory processes affecting the brains of stroke-prone rats. J Pharmacol Exp Ther 2010;335: 324-331.
13. Pereira MG, Cǎmara NO, Campaholle G, et al. Pioglitazone limits cyclosporine nephrotoxicity in rats. Int Immunopharmacol 2006;6: 1943-1951.
14. Asvadi I, Hajipour B, Asvadi A, et al. Protective effect of pentoxyfilline in renal toxicity after methotrexate administration. Eur Rev Med Pharmacol Sci 2011;15: 1003-1009.
15. El-Sheikh AA, Morsy MA, Mahmoud MM, et al. Effect of coenzyme-Q10 on doxorubicin-induced nephrotoxicity in rats. Adv Pharmacol Sci 2012;2012:981461. doi: 10.1155/2012/981461.
16. Mihara M, Uchiyama M. Properties of thiobarbituric acid-reactive materials obtained from lipid peroxide and tissue homogenate. Chem Pharm Bull (Tokyo) 1983;31: 605-611.
17. Fendler C, Braun J. Use of methotrexate in inflammatory myopathies. Clin Exp Rheumatol 2010;28:S164-S167.
18. Abraham P, Kolli VK, Rabi S. Melatonin attenuates methotrexateinduced oxidative stress and renal damage in rats. Cell Biochem Funct 2010;28: 426-433.
19. Uz E, Oktem F, Yilmaz HR, et al. The activities of purinecatabolizing enzymes and the level of nitric oxide in rat kidneys subjected to methotrexate: protective effect of caffeic acid phenethyl ester. Mol Cell Biochem 2005;277: 165-170.
20. Oktem F, Yilmaz HR, Ozguner F, et al. Methotrexate-induced renal oxidative stress in rats: the role of a novel antioxidant caffeic acid phenethyl ester. Toxicol Ind Health 2006;22: 241-247.
21. Kolli VK, Abraham P, Isaac B, Selvakumar D. Neutrophil infiltration and oxidative stress may play a critical role in methotrexate-induced renal damage. Chemotherapy 2009;55: 83-90.
22. Isshiki K, Haneda M, Koya D, et al. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulinsensitizing action in diabetic rats. Diabetes 2000;49: 1022-1032.
23. Xu X, Chen P, Zheng Q, et al. Effect of pioglitazone on diabetic nephropathy and expression of HIF-1α and VEGF in the renal tissues of type 2 diabetic rats. Diabetes Res Clin Pract 2011;93: 63-69.
24. Ohga S, Shikata K, Yozai K, et al. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. Am J Physiol Renal Physiol 2007;292:F1141-F1150.
25. Jesse CR, Bortolatto CF, Wilhelm EA, et al. The peroxisome proliferator-activated receptor-γ agonist pioglitazone protects against cisplatin-induced renal damage in mice. J Appl Toxicol 2014;34: 25-32.
26. Polvani S, Tarocchi M, Galli A. PPARg and oxidative stress: Con(β) catenating NRF2 and FOXO. PPAR Res 2012;2012:641087. doi: 10.1155/2012/641087.
27. Balakumar P, Kadian S, Mahadevan N. Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney? Pharmacol Res 2012;65: 430-436.
28. Zak Z, Gelebart P, Lai R. Fenofibrate induces effective apoptosis in mantle cell lymphoma by inhibiting the TNFalpha/NF-KappaB signaling axis. Leukemia 2010;24: 1476-1486.
29. Belfort R, Berria R, Cornell J, Cusi K. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J Clin Endocrinol Metab 2010;95: 829-836.
30. Liu SN, Liu Q, Li LY, et al. Long-term fenofibrate treatment impaired glucose-stimulated insulin secretion and up-regulated pancreatic NF-Kappa B and iNOS expression in monosodium glutamate-induced obese rats: is that a latent disadvantage? J Transl Med 2011;9:176. doi: 10.1186/1479-5876-9-176.
31. Toblli JE, Cao G, Giani JF, et al. Antifibrotic effects of pioglitazone at low doses on the diabetic rat kidney are associated with the improvement of markers of cell turnover, tubular and endothelial integrity, and angiogenesis. Kidney Blood Press Res 2011;34: 20-33.